Osteoporosis is associated with high risk for coronary heart disease

Medicine (United States)

Volumn 94, Issue 27, 2015, Pages e1146-

  Chen, Sy Jou ^a   Lin, Chin Sheng ^a   Lin, Cheng Li ^b,c   Kao, Chia Hung ^b,c  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; ESTROGEN;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HAZARD RATIO; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; CORONARY DISEASE; INCIDENCE; MIDDLE AGED; RISK FACTOR; TAIWAN;

AGED; COMORBIDITY; CORONARY DISEASE; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; OSTEOPOROSIS; RETROSPECTIVE STUDIES; RISK FACTORS; TAIWAN;

EID: 84941132467     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000001146     Document Type: Article

References (43)

1. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis and Therapy, March 7-29, 2000: highlights of the conference. South Med J. 2001; 94: 569-573
2. Hamel P, Abed E, Brissette L, et al. Characterization of oxidized low-density lipoprotein-induced hormesis-like effects in osteoblastic cells. Am J Physiol Cell Physiol. 2008; 294: C1021-C1033
3. Mackie EJ. Osteoblasts: novel roles in orchestration of skeletal architecture. Int J Biochem Cell Biol. 2003; 35: 1301-1305
4. WRITING GROUP MEMBERSLloyd-Jones D, Adams RJ, et al. Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation. 2010; 121: e46-e215
5. Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med. 2011; 17: 1410-1422
6. Tabas I. Pulling down the plug on atherosclerosis: finding the culprit in your heart. Nat Med. 2011; 17: 791-793
7. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005; 352: 1685-1695
8. Moore KJ, Tabas I. Macrophages in the pathogenesis of atherosclerosis. Cell. 2011; 145: 341-355
9. Williams KJ, Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol. 1995; 15: 551-561
10. Kwon GP, Schroeder JL, Amar MJ, et al. Contribution of macromolecular structure to the retention of low-density lipoprotein at arterial branch points. Circulation. 2008; 117: 2919-2927
11. Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat Immunol. 2011; 12: 204-212
12. Farhat GN, Cauley JA. The link between osteoporosis and cardiovascular disease. Clin Cases Miner Bone Metab. 2008; 5: 19-34
13. Anagnostis P, Karagiannis A, Kakafika AI, et al. Atherosclerosis and osteoporosis: age-dependent degenerative processes or related entities?. Osteoporos Int. 2009; 20: 197-207
14. Farhat GN, Newman AB, Sutton-Tyrrell K, et al. The association of bone mineral density measures with incident cardiovascular disease in older adults. Osteoporos Int. 2007; 18: 999-1008
15. Den Uyl D, Nurmohamed MT, van Tuyl LH, et al. (Sub)clinical cardiovascular disease is associated with increased bone loss and fracture risk; a systematic review of the association between cardiovascular disease and osteoporosis. Arthritis Res Ther. 2011; 13: R5
16. Price PA, Faus SA, Williamson MK. Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption. Arterioscler Thromb Vasc Biol. 2001; 21: 817-824
17. Mezquita-Raya P, de la Higuera M, García DF, et al. The contribution of serum osteoprotegerin to bone mass and vertebral fractures in postmenopausal women. Osteoporos Int. 2005; 16: 1368-1374
18. Soufi M, Schoppet M, Sattler AM, et al. Osteoprotegerin gene polymorphisms in men with coronary artery disease. J Clin Endocrinol Metab. 2004; 89: 3764-3768
19. Lin T, Liu JC, Chang LY, et al. Association between coronary artery calcification using low-dose MDCT coronary angiography and bone mineral density in middle-aged men and women. Osteoporos Int. 2011; 22: 627-634
20. Tanko LB, Christiansen C, Cox DA, et al. Relationship between osteoporosis and cardiovascular disease in postmenopausal women. J Bone Miner Res. 2005; 20: 1912-1920
21. Marcovitz PA, Tran HH, Franklin BA, et al. Usefulness of bone mineral density to predict significant coronary artery disease. Am J Cardiol. 2005; 96: 1059-1063
22. Bauer DC, Bauer DC, Palermo L, et al. Quantitative ultrasound and mortality: a prospective study. Osteoporos Int. 2002; 13: 606-612
23. Kado DM, Browner WS, Blackwell T, et al. Rate of bone loss is associated with mortality in older women: a prospective study. J Bone Miner Res. 2000; 15: 1974-1980
24. Mussolino ME, Madans JH, Gillum RF. Bone mineral density and mortality in women and men: the NHANES I epidemiologic followup study. Ann Epidemiol. 2003; 13: 692-697
25. Magnus JH, Broussard DL. Relationship between bone mineral density and myocardial infarction in US adults. Osteoporos Int. 2005; 16: 2053-2062
26. Doherty TM, Asotra K, Fitzpatrick LA, et al. Calcification in atherosclerosis: bone biology and chronic inflammation at the arterial crossroads. Proc Natl Acad Sci USA 2003; 100: 11201-11206
27. Abedin M, Tintut Y, Demer LL. Vascular calcification: mechanisms and clinical ramifications. Arterioscler Thromb Vasc Biol. 2004; 24: 1161-1170
28. Rubin MR, Silverberg SJ. Vascular calcification and osteoporosis-the nature of the nexus. J Clin Endocrinol Metab. 2004; 89: 4243-4245
29. Hyder JA, Allison MA, Wong N, et al. Association of coronary artery and aortic calcium with lumbar bone density: the MESA Abdominal Aortic Calcium Study. Am J Epidemiol. 2009; 169: 186-194
30. Hamerman D. Osteoporosis and atherosclerosis: biological linkages and the emergence of dual-purpose therapies. QJM. 2005; 98: 467-484
31. Detrano R, Guerci AD, Carr JJ, et al. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med. 2008; 358: 1336-1345
32. Thompson GR, Partridge J. Coronary calcification score: the coronary-risk impact factor. Lancet. 2004; 363: 557-559
33. Adami S, Braga V, Zamboni M, et al. Relationship between lipids and bone mass in 2 cohorts of healthy women and men. Calcif Tissue Int. 2004; 74: 136-142
34. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998; 93: 165-176
35. Silva I, Branco JC. Rank/Rankl/opg: literature review. Acta Reumatol Port. 2011; 36: 209-218
36. Lambrinoudaki I, Armeni E, Georgiopoulos G, et al. Subclinical atherosclerosis in menopausal women with low to medium calculated cardiovascular risk. Int J Cardiol. 2013; 164: 70-76
37. Khosla S. Pathogenesis of age-related bone loss in humans. J Gerontol A Biol Sci Med Sci. 2013; 68: 1226-1235
38. Falahati-Nini A, Riggs BL, Atkinson EJ, et al. Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J Clin Invest. 2000; 106: 1553-1560
39. Fiore CE, Pennisi P, Pulvirenti I, et al. Bisphosphonates and atherosclerosis. J Endocrinol Invest. 2009; 32: 38-43Review
40. Strandberg TE. Alendronate, osteoporosis, and atherosclerosis. Arch Intern Med. 2008; 168: 2386-2387author reply 2387
41. Adami S, Braga V, Guidi G, et al. Chronic intravenous aminobisphosphonate therapy increases high-density lipoprotein cholesterol and decreases low-density lipoprotein cholesterol. J Bone Miner Res. 2000; 15: 599-604
42. Ariyoshi T, Eishi K, Sakamoto I, et al. Effect of etidronic acid on arterial calcification in dialysis patients. Clin Drug Investig. 2006; 26: 215-222
43. Kang JH, Keller JJ, Lin HC. Bisphosphonates reduced the risk of acute myocardial infarction: a 2-year follow-up study. Osteoporos Int. 2013; 24: 271-277